TearScience® Solution Helps Vision Source Members Better Serve Dry Eye Patients
MORRISVILLE, N.C.─May 20, 2013─TearScience®, a privately held medical device company, today announced an agreement with Vision Source, a network of private practice optometrists that share knowledge and resources to provide the best eye care, to make TearScience’s solution for identifying and treating evaporative dry eye available to its members. Vision Source members are well known for pioneering advanced technology in their eye care practices.
More than 23 million Americans suffer from dry eye disease. With the majority (86 percent) suffering from evaporative dry eye, this represents a more than $10 billion market potential in North America. TearScience® has developed and launched its solution to address this underserved patient population. The solution includes the LipiView® Ocular Surface Interferometer and the LipiFlow® Thermal Pulsation System. Evaporative dry eye occurs when Meibomian glands in the eyelids become obstructed and do not secrete the oily lipids needed to keep the water portion of tears from evaporating too quickly. LipiView® measures the absolute thickness of the lipid layer of a dry eye patient’s tear film and helps identify if a dry eye patient is a partial blinker, a condition that may limit lipid production and impact the ocular surface. LipiFlow® treats the root cause of evaporative dry eye disease by unblocking obstructed Meibomian glands during an in-office procedure.
“Meibomian Gland Dysfunction is a highly common and progressive disease,” said John McCall, OD, senior vice president of vendor relations for Vision Source. “Vision Source members recognize the importance of identifying and treating this chronic condition early. Our partnership with TearScience® will help our members stay at the forefront of managing this chronic disease.”
TearScience® exhibited at Vision Source’s annual meeting in Las Vegas from April 24-27, 2013.
“The annual meeting provided a great opportunity for TearScience® to engage Vision Source members,” said Wade Hampton, TearScience’s chief commercial officer. “The response to our technology at the meeting exceeded our expectations. Vision Source and TearScience® share the common goal of wanting to provide the best care to dry eye patients. Using our LipiView® and LipiFlow® technology, Vision Source members differentiate their practices with the ultimate goal of increasing dry eye patient satisfaction.”
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 86 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye, obstructed Meibomian glands. For additional information, visit www.tearscience.com.
About Vision Source
Vision Source was founded in 1991 with the belief that eye health care is best provided by an independent family eye doctor, free to make his or her own decisions about what is best for the continued good vision of the patient. As a member of Vision Source, a private practice optometrist has access to the shared knowledge and resources of a network with more than 2,700 offices. Because each office is independently owned and operated, your entire eye care experience – from examination through fitting of eyeglasses or contacts – takes place under the watchful eye of your family optometrist.
# # #